Iowa City, IANCT03096418Now EnrollingIRB Ready

Breast Neoplasm Female Clinical Trial in Iowa City, IA

Access cutting-edge breast neoplasm female treatment through this phase 4 clinical trial at a research site in Iowa City. Study-provided care at no cost to qualified participants.

Sponsored by University of Wisconsin, Madison

Quick Self-Assessment

See if you qualify for this Iowa City location

Preparing your pre-screening questions…

Expert Care in Iowa City

Access breast neoplasm female specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related breast neoplasm female treatment provided free

Apply for This Iowa City Location

Check if you qualify for this breast neoplasm female clinical trial in Iowa City, IA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Iowa City

    Convenient for IA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Iowa City site if eligible
  4. 4Begin participation

About This Breast Neoplasm Female Study in Iowa City

The hypothesis of this study is that paclitaxel levels increase chromosomal instability (CIN) in tumors and this is lethal to tumors that have pre-existing CIN. Treatment will be administered on an outpatient basis. Paclitaxel will be initiated as standard infusions on days 1, 8, and 15 of a 21-day cycle. Participants will continue with paclitaxel for cycles 2-4 prior to surgery.

Sponsor: University of Wisconsin, Madison

Who Can Participate

Inclusion Criteria

Women with pathologically demonstrated breast cancer
Patients must be candidates for neoadjuvant paclitaxel chemotherapy by their treating oncologist. No other investigational or commercial therapeutic agents may be given concurrently with the paclitaxel.
Patients must not have metastatic disease on staging work-up per institutional guidelines.
A formalin-fixed paraffin embedded tumor block (preferred) or unstained slides must be available from a prior biopsy of the primary tumor (preferred) or lymph node. A minimum of 8 slides must be available.
The primary tumor or lymph node must be readily biopsied by surgery or radiology teams.
The primary tumor must be measurable by an imaging modality prior to treatment. This imaging modality is to be repeated after completion of 4 cycles of paclitaxel and prior to surgery. Such imaging modalities may include ultrasound, CT, mammography, or MRI. MRI will be the preferred imaging modality if available because it has the highest accuracy and positive predictive value for predicting pathologic complete response.All imaging will be performed per standard of care at the discretion of the treating physicians.
Subjects may not have had prior systemic chemotherapy regimens administered for treatment of their current breast cancer. However, studies (window studies, for example) that are deemed non-therapeutic, including those that utilize agents that are not FDA approved for the treatment of the patient's current breast cancer, are permitted.
Patients must have adequate organ and marrow function as determined by the treating oncologist.
Patient must be willing to undergo additional biopsy of breast tumor or lymph node.
Patient must have the ability and willingness to sign a written informed consent document.
Women of childbearing potential (per institutional policy) must agree to use effective contraception as discussed with treating oncologist for the duration of the study.

Exclusion Criteria

History of allergic reactions attributed to compounds of similar chemical or biologic composition to paclitaxel including to other drugs formulated in Cremophor(R) EL (polyoxyethylated castor oil).
Patients with known HIV due to concern that chemotherapy may cause further immunosuppression and potential infectious complications.
Patients on non-aspirin anti-coagulation (Coumadin, heparins, or clopidogrel) or with documented bleeding disorders will be excluded due to risk of bleeding with biopsy.
Uncontrolled intercurrent illness including, but not limited to, ongoing or active severe infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, other malignancies requiring therapy or psychiatric illness/social situations that would limit compliance with study requirements as determined by treatment physician.
Pregnant women are excluded from this study because paclitaxel is a pregnancy category D drug and may cause deleterious effects to the fetus. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with paclitaxel, breastfeeding should be discontinued if the mother is enrolled in the trial.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Iowa City?

Yes, this clinical trial (NCT03096418) has an active research site in Iowa City, IA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Breast Neoplasm Female Treatment Options in Iowa City, IA

If you're searching for breast neoplasm female treatment options in Iowa City, IA, this clinical trial (NCT03096418) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Iowa City research site is actively enrolling participants for this phase 4 clinical trial. You'll receive care from experienced breast neoplasm female specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all breast neoplasm female clinical trials near you to find additional studies recruiting in your area.

More Breast Cancer Trials in Iowa City, IA

See all breast cancer clinical trials recruiting in Iowa City — not just this study.

Browse Breast Cancer Trials in Iowa City →

Browse More Trials by Condition

Breast Cancer TrialsAnkylosing Spondylitis TrialsAll Conditions →

Ready to Join in Iowa City?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Iowa City, IA